The metabolic syndrome in long-term cancer survivors, and important target for secondary preventive measures☆
Abstract
With increasing numbers of cancer survivors, attention has been drawn to long-term complications of curative cancer treatment, including a range of metabolic disorders. These metabolic disorders often resemble the components of the so-called metabolic syndrome, or syndrome X, which is an important risk factor for the development of cardiovascular disease. The mechanisms behind the development of metabolic disorders in cancer survivors have not been fully elucidated. However, association studies in the general population have demonstrated correlations between the components of the metabolic syndrome on the one hand and hormonal deficiencies, hypomagnesaemia, and endothelial dysfunction on the other. These latter disorders are regularly reported following curative cancer treatment and could, therefore, be important aetiologic factors in the development of the metabolic syndrome in cancer survivors. This review discusses data on the associations between the metabolic syndrome and treatment-related complications in cancer survivors and possibilities for preventive measures.
Keywords: long-term cancer survivors, metabolic syndrome, syndrome X, hormones, magnesium, endothelial dysfunction
To access this article, please choose from the options below
☆ Supported by Grant RUG2000-2177 from the Dutch Cancer Society.
PII: S0305-7372(02)00038-5
© 2002 Elsevier Science Ltd. All rights reserved.
